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Abstract: Inadequacy of antioxidant nuclear factor-E2-related factor 2 (Nrf2) and endoplasmic 
reticulum stress-mediated unfolded protein response has been implicated in severe chronic 
obstructive pulmonary disease (COPD) and cigarette smoking-induced emphysema. As evi-
dence suggests that the ability to upregulate Nrf2 expression may influence the progression 
of COPD and no data exist up to now in ex-smokers with mild–moderate COPD, this study 
was first aimed to evaluate Nrf2 and unfolded protein response expression in peripheral blood 
mononuclear cells (PBMC) of mild–moderate ex-smokers with COPD compared to smoking 
habit-matched non-COPD subjects. Then, we tested whether oxidative stress persists after 
cigarette smoking cessation and whether the concentrations of oxidized phospholipids (oxida-
tion products of the phospholipid 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine 
[oxPAPC]) in the PBMC of the same subjects may have a causative role in determining the 
upregulation of Nrf2. The expression (mRNA and protein) of Nrf2 and of its related gene heme 
oxygenase-1 was significantly increased in COPD group without differences in the unfolded 
protein response. Plasma malondialdehyde, the circulating marker of oxidative stress, and 
oxPAPC in PBMC were significantly higher in COPD than in non-COPD subjects. The fact 
that the expression of p47phox, a subunit of NADPH oxidase, was increased in PBMC of 
COPD patients and that it was directly correlated with oxPAPC may indicate that oxPAPC 
may be one of the determinants of oxidative stress-induced Nrf2 upregulation. Finally, we 
also demonstrated that lung function inversely correlated with plasma malondialdehyde and 
with Nrf2 and heme oxygenase-1 mRNA expression in all subjects. Our results indicate that 
mild–moderate ex-smokers with COPD may be able to counteract oxidative stress by increas-
ing the expression of Nrf2/antioxidant-response elements. Because Nrf2 failure significantly 
contributes to the development of COPD, our findings suggest that the possibility to prevent 
Nrf2 reduction may open a new scenario in helping to prevent the oxidative stress-associated 
lung function decline.
Keywords: mild–moderate COPD, Nrf2/ARE, UPR, oxidative stress, cigarette smoking, 
peripheral blood mononuclear cells
Introduction
Chronic obstructive pulmonary disease (COPD) is a common disease affecting millions 
of people worldwide characterized by progressive airflow limitation, destruction of the 
lung parenchyma, and various systemic manifestations, which significantly impact 
mortality.1 Although cigarette smoking (CS) is the major risk factor for COPD,1 the 
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fact that only a minority of smokers develop COPD2 and that 
CS cessation is ineffective at halting disease3 has led to the 
suggestion that other endogenous factors may also be driv-
ing the disease. Convincing evidence suggests that oxidative 
stress and inflammation play a key pathogenetic role in COPD 
onset and progression.4,5 In COPD patients, oxidative stress 
results from an increase of reactive oxygen species (ROS) 
present in CS per se, as well as generated by various inflam-
matory, immune, and epithelial cells of the airways.5 Increased 
oxidative stress, in turn, sustains pulmonary inflammation 
that induces recruitment and activation of immune cells into 
the lungs,5 producing inflammatory mediators that may spill 
over into the systemic circulation.1 It has been suggested that 
host ability to defend from oxidative stress by upregulating 
lung antioxidant defenses may be one of the critical events 
that determines the severity and progression of COPD.6 The 
nuclear factor-E2-related factor 2 (Nrf2) is a master tran-
scription factor that regulates antioxidant-response element 
(ARE)-mediated expression of cytoprotective proteins and 
antioxidant enzymes, such as heme oxygenase-1 (HO-1). 
Under basal conditions, Nrf2-dependent transcription is 
repressed by its negative regulator Kelch-like ECH-associated 
protein 1; when cells are exposed to oxidative stress or 
electrophiles, Nrf2 accumulates in the nucleus and drives 
the expression of its target genes.7 There are significant data 
suggesting a critical role for Nrf2 in preventing lung disease; 
in this context, previous studies have shown an increased 
susceptibility to CS-induced emphysema in Nrf2-deficient 
mice8 and a decline of Nrf2 expression in pulmonary mac-
rophages of current smokers and COPD patients.9 Recent 
evidence demonstrates that endoplasmic reticulum (ER) 
stress is a form of intracellular stress that occurs whenever 
the protein-folding capacity of the ER is overwhelmed.10 This 
accumulation of unfolded and misfolded proteins activates 
transcriptional and translational pathways, known as unfolded 
protein response (UPR). When UPR is induced, the three 
ER transmembrane sensors, protein kinase-like ER kinase 
(PERK), inositol-requiring kinase 1 (IRE1), and the transcrip-
tional factor activating transcription factor 6 (ATF6), which 
are maintained in an inactive state through interaction with 
binding immunoglobulin protein (BiP) become activated to 
initiate adaptive responses.10 Once the UPR fails to control the 
level of unfolded and misfolded proteins in the ER, apoptotic 
signaling is induced through the expression of the death fac-
tor, CCAAT/enhancer-binding protein homologous protein 
(CHOP).11 Former research has shown that CS extract causes 
ER stress and apoptosis in human bronchial epithelial cells and 
in mice12 and chronic CS exposure induces UPR activation in 
lungs of smokers13 and patients with COPD.13,14 Furthermore, 
an increased ER stress, particularly an overexpression of 
apoptotic mediators, has been recently demonstrated in lung 
tissues of COPD patients with severe emphysema.15 Peripheral 
blood mononuclear cells (PBMC) are the progenitors of the 
alveolar macrophages that play a crucial role in maintaining 
and controlling the inflammatory process in COPD.16 We have 
previously shown that oxidation products of the phospholipid 
1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine 
(oxPAPC) increased the generation of ROS in PBMC through 
the activation of nicotinamide adenine dinucleotide phos-
phate (NADPH) oxidase,17 and the increase of oxPAPC in 
PBMC was associated with the activation of the Nrf2/ARE 
pathway in mild smokers compared to nonsmokers, whereas 
in heavy smokers the Nrf2/ARE expression was similar to 
nonsmokers.17 COPD is typically diagnosed late in the course 
of disease when the symptoms become clinically evident18 
and consequently very few studies have focused on oxidative 
stress in its early phases, potentially crucial for the subsequent 
evolution of airway damage. Moreover, it is uncertain whether 
systemic and cellular oxidative stress is still present after long-
term CS cessation;3 no data exist up to now on Nrf2/ARE and 
UPR expression in mild–moderate ex-smokers with COPD. 
Therefore, this study was performed in ex-smokers with 
COPD with mild–moderate bronchial obstruction compared 
to age-, sex-, and smoking habit-matched non-COPD subjects 
and aimed to evaluate: 1) the expression of Nrf2, HO-1, and 
UPR in PBMC; 2) circulating markers of oxidative stress 
and inflammation; 3) whether cellular oxidative stress, and 
in particular oxPAPC, may contribute to PBMC gene expres-
sion; and 4) the possible correlations between lung function 
and circulating markers of oxidative stress and antioxidant 
gene expression.
Materials and methods
Ethics statement
The study was approved by the ethics committee of the 
Azienda Ospedaliera Universitaria Integrata Verona, in 
accordance with the standards of the Declaration of Helsinki, 
and written informed consent was obtained from all the 
patients before their enrollment.
Study population
In this study, we enrolled two groups of subjects: one group 
was composed of 30 consecutive, ex-smokers mild–moderate 
(16 mild and 14 moderate) COPD patients referring to 
Respiratory Medicine Outpatient Clinic of our Institution. 
The Global initiative for chronic Obstructive Lung Disease 
guideline was used to make the diagnosis and to grade COPD 
severity.19 The other group comprised age-, sex-, and smoking 
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habit-matched non-COPD subjects randomly selected from 
the general population.20 Major requirements for the enroll-
ment of both groups were absence of infectious or acute/
chronic inflammatory diseases or known cardiovascular 
diseases, malignancy, and absence of acute/chronic renal 
failure and hepatic failure. No COPD subjects were using 
supplemental oxygen, glucocorticoids, antibiotic, and bron-
chodilator agents. Past smoking exposure was evaluated 
as years of smoking duration and pack-years, which is an 
indicator of a person’s cumulative cigarette consumption. 
Pack-years have been calculated by multiplying the number 
of packs of cigarettes smoked per day by the number of years 
the subject had smoked. All subjects reported that they had 
discontinued smoking for at least 1 year. All subjects under-
went clinical evaluation and pulmonary function test.
Pulmonary function test
Forced expiratory volume in 1 second (FEV1) and FEV1/
forced vital capacity (FVC) were measured using a water-
sealed spirometer (Biomedin, Padua, Italy). Lung function 
values were expressed as a percentage of predicted values, 
and the lower limit of normal low limit of normality for the 
FEV1/FVC was calculated according to Quanjer.
21
Blood samples and PBMC isolation
Venous blood samples were obtained from non-COPD and 
COPD subjects after 12 hours fasting. Blood was collected 
from each subject and drawn into pyrogen-free blood 
collection tubes. Multiple aliquots of plasma were placed into 
sterile 1 mL screw-capped polypropylene vials containing 
the phenolic antioxidant 2,6-di-tert-butyl-4-methylphenol 
(10 mM; Sigma-Aldrich Co., St Louis, MO, USA) to 
inhibit lipid peroxidation and stored at ?80?C. The samples 
were frozen and thawed only once. PBMC were isolated as 
previously described.22 Blood samples were collected from 
subjects into sodium heparin-buffered Vacutainer® CPT™ 
tubes (from Becton Dickinson). The BD CPT™ tube is an 
evacuated tube containing anticoagulant, separation gel, and 
density gradient liquid. Whole blood is collected, centrifuged, 
and processed entirely within this tube. The CPT™ contains 
a gel barrier and Ficoll to allow for separation of PBMC 
and plasma from erythrocytes and granulocytes following 
a single centrifugation step. Immediately following blood 
collection with Vacutainer® CPT™, the tubes were inverted 
ten times and centrifuged at 1,500? g for 20 minutes at room 
temperature. After centrifugation, the PBMC layer was gently 
suspended in the plasma and transferred to 15 mL conical 
tubes and washed with phosphate-buffered saline by cen-
trifugation at 300? g for 10 minutes. Monocyte purity was 
greater than 97% as assessed by flow cytometry. C-reactive 
protein (CRP) was measured using a commercially avail-
able high-sensitivity turbidimetric method (Syncron-PCR; 
Beckman Coulter, Brea, CA, USA).
Glutathione measurement in plasma
The detailed procedure for the measurement of plasma gluta-
thione (GSH) has been previously described.23 Samples were 
derivatized with 7-fluorobenzo-2-oxa-1,3-diazol-4-sulfonic 
acid and quantitated using high-performance liquid chroma-
tography with fluorescence detection. Fluorimetric detector 
was a Shimadzu RF-10 Axl and was set with ?ex ?385 nm 
and ?em ?515 nm.
Malondialdehyde measurement in plasma
The detailed procedure for the measurement of plasma 
malondialdehyde (MDA) has been previously described.24 
Briefly, 400 ?L of phosphoric acid solution (44 mM) and 
100 ?L of thiobarbituric acid solution (42 mM) were added 
to 150 ?L of plasma sample. Then, samples were heated at 
100?C for 60 minutes, extracted with 250 ?L of n-butanol; 
20 ?L of each sample was injected into the column. MDA 
was measured by high-performance liquid chromatography 
with fluorescence detection. Fluorimetric detector was a 
Shimadzu RF-10 Axl and was set with ?ex ?520 nm and 
?em ?542 nm.
oxPAPC measurement in PBMC
Among the different oxPAPC, 1-palmitoyl-2-(5-oxovaleroyl)-
sn-glycero-3-phosphorylcholine (POVPC) and 1-palmitoyl-
2-glutaroyl-sn-glycero-3-phosphorylcholine (PGPC) were 
taken into consideration in this study because they have been 
previously identified as the most bioactive components.25 
Measurement of POVPC and PGPC was obtained on an 
Agilent 1100 (Agilent Technologies, Santa Clara, CA, USA) 
mass spectrometer equipped with an electrospray ion source, 
as previously described.25 Quantification of the peak areas 
was performed by single-ion monitoring in the elution time 
range of 10–20 minutes using appropriate software. Authentic 
1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine, 
POVPC, and PGPC were obtained from Avanti Polar Lipids, 
Inc. (Alabaster, AL, USA).
Quantitative real-time polymerase chain 
reaction
Quantitative real-time polymerase chain reaction (PCR) 
analysis was performed as previously described.22 Total RNA 
was extracted from PBMC with an RNeasy Mini Kit (Qiagen, 
Milan, Italy) and reverse transcribed using an IScript cDNA 
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Synthesis Kit (Bio-Rad Laboratories Inc., Hercules, CA, 
USA). Real-time RT-PCR was conducted by iCycler themo-
cycler (Bio-Rad Laboratories Inc.) using IQSYBR Green 
SuperMix (Bio-Rad Laboratories Inc.) and 300 pmol/mL each 
primer pair. Primer design was done with Beacon Design 4.0 
software (PREMIER Biosoft International, Palo Alto, CA, 
USA): Nrf2, sense 5?-TTCAGCCAGCCCAGCACATC-3? 
and antisense 5?-CGTAGCCGAAGAAACCTCATTGTC-3?; 
HO-1, sense 5?-GGTGACCCGAGACGGCTTC-3? and anti-
sense 5?-AGACTGGGCTCTCCTTGTTGC-3?; p47phox, 
sense 5?-CCCACAGACAACCAGACAAA-3?, antisense 
5?-TTTGTCTGGTTGTCTGTGGG-3?; ?-actin, sense 
5?-ATCAAGATCATTGCTCCTCCTG-3? and anti-
sense 5?-GCAACTAAGTCATAGTCCGCC-3?. All primers 
were optimized to an equal annealing temperature of 60?C, 
a similar GC content, and supplied by MWG-Biotech AG 
(Ebersberg, Germany). Cycling conditions were: 3 minutes 
at 95?C, followed by 50 cycles during 10 seconds at 95?C, 
30 seconds at 60?C, and 1 minute at 55?C. The relative expres-
sion levels of mRNA encoding UPR genes were performed 
using the QuantiTect Primer Assay and QuantiTect SYBR 
Green PCR Kit (Qiagen) on the MyiQ Thermal Cycler (Bio-
Rad Laboratories Inc.). QuantiTect Hs-ACTB Assay (Qiagen) 
was used as a normalizer. UPR QuantiTect Primer Assays 
were purchased from Qiagen: BiP: QT00096404, PERK: 
QT00066003, IRE1: QT00025760, ATF6: QT00083370, 
CHOP: QT00082278, and ?-actin: QT00095431. They are 
bioinformatically validated primer sets for use in SYBR 
Green-based real-time RT-PCR at an annealing temperature 
of 55?C, in accordance with the specifications provided by 
the supplier. Cycling conditions were: 15 minutes at 95?C, 
followed by 40 cycles during 15 seconds at 94?C, 30 seconds 
at 55?C, and 30 seconds at 72?C. Normalized gene expression 
levels are given as the ratio between the mean value for the 
target gene and ?-actin in each sample.
Western blotting
Western blot analysis was performed as previously 
described.22 Nrf2, HO-1, BiP, PERK, IRE1, ATF6, CHOP, 
and p47phox were immunoprecipitated from 1 mg of each 
PBMC nuclear lysate or protein lysate with mouse monoclo-
nal antibodies and anti-?-actin (Santa Cruz Biotechnology, 
Heidelberg, Germany). Immune complexes were captured 
with protein A/G–Sepharose beads (Pierce, Rockford, IL, 
USA) for 2 hours, and the beads were washed four times 
with 100 mM NaCl. Nrf2 (sc-722), HO-1 (sc-10789), BiP 
(sc-1050), PERK (sc-13073), IRE1 (sc-20790), ATF6 
(sc-22799), CHOP (sc-7351), and p47phox (sc-14015) were 
detected by probing immunoprecipitates with rabbit poly-
clonal antibodies (Santa Cruz Biotechnology), followed by 
goat antirabbit horseradish peroxidase-conjugated secondary 
antibody (Bio-Rad Laboratories Inc.). Reactive antigens were 
visualized with Supersignal chemiluminescence substrate 
(Pierce) and quantified by densitometric analysis with Chemi-
Doc XRS (Bio-Rad Laboratories Inc.). Protein expression 
data were quantified with Quantity One Software (Bio-Rad 
Laboratories Inc.).
Statistical analysis
Data are expressed as mean ? standard deviation values. Dif-
ferences between the groups were analyzed by a two-tailed 
unpaired Student’s t-test. The relationship between variables 
was assessed by linear regression. Statistical analysis of the 
data was conducted using SPSS version 20.0 (IBM Corpo-
ration, Armonk, NY, USA); P?0.05 was considered to be 
statistically significant.
Results
Lung function, clinical, and laboratory 
characteristics
Lung function and medical history of subjects participating in 
the study are reported in Table 1. According to the inclusion 
criteria, FEV1 and FEV1/FVC resulted significantly lower in 
Table 1 GOLD stage, lung function, and medical history of non-
COPD and COPD subjects
Non-COPD
N?30
COPD
N?30
P-value
Age (years) 67.8?6.8 69.3?6.6 NS
Sex (M/F) 24/6 23/7 NS
Past smoking exposure  
(pack-years)
27.8?36.6 34.2?26 NS
Duration of smoking (years) 23.8?11.2 27.5?12.4 NS
GOLD 1 n (%) 0 16 (53.3%)
GOLD 2 n (%) 0 14 (46.7%)
FEV1 (L) 2.98?0.7 1.95?0.7 0.001
FEV1 (% of predicted) 105.0?16.8 75.06?20.2 0.001
FEV1/FVC 75.3?4.5 58.0?8.4 0.001
SpO2 (%) 97.5?1.4 95.3?2.6 0.01
Hypertension (%) 70 76.7 NS
Type 2 diabetes mellitus (%) 20 23.3 NS
Dyslipidemia (%) 83.3 73.3 NS
Antihypertensive drug  
use (%)
41.4 66.6 0.01
Oral antidiabetic drug  
use (%)
13.3 13.3 NS
Statin use (%) 20 40 0.01
Note: Data are expressed as mean ? SD unless otherwise stated.
Abbreviations: COPD, chronic obstructive pulmonary disease; F, female; FEV1, 
forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global 
initiative for chronic Obstructive Lung Disease; M, male; NS, not signiﬁcant; 
SD, standard deviation; SpO2, percutaneous oxygen saturation.
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COPD than non-COPD subjects (P?0.01). Smoking habits, 
prevalence of hypertension, diabetes, and dyslipidemia 
were similar in COPD and non-COPD subjects. As shown 
in Table 2, also anthropometric characteristics, plasma glu-
cose, triglycerides, high-density lipoprotein cholesterol, and 
diastolic blood pressure were comparable in both groups. 
On the contrary, COPD subjects presented lower values of 
systolic blood pressure and total and low-density lipoprotein 
cholesterol (all P?0.01) than non-COPD subjects. These 
results are probably due to the fact that treatment with anti-
hypertensive drugs and statins was more frequent in patients 
with COPD, as reported in Table 1.
Nrf2, HO-1, and UPR expression in 
PBMC derived from non-COPD and 
COPD subjects
We evaluated the expression of Nrf2, HO-1, and UPR 
(BiP, ATF6, PERK, IRE1, and CHOP) in PBMC derived 
from non-COPD and COPD subjects; our results show an 
increased mRNA and protein expression of both Nrf2 and 
HO-1 (P?0.001) in PBMC derived from COPD compared to 
non-COPD subjects (Figure 1A and B). On the contrary, UPR 
(BiP, ATF6, PERK, IRE1, and CHOP) mRNA and protein 
expression were similar in both groups (Figure 2A and B).
Circulating markers of oxidative stress 
and inﬂammation
The plasma concentrations of MDA resulted higher in COPD 
than in non-COPD subjects (P?0.01), whereas plasma con-
centrations of GSH were significantly higher in the latter than 
in the former (P?0.01) (Figure 3). Moreover, high-sensitivity 
CRP concentrations (P?0.01) and white blood count were 
significantly higher (P?0.02) in COPD than in non-COPD 
subjects (Table 2).
Concentrations of oxPAPC and 
expression of p47phox in PBMC
In order to ascertain whether the increased expression of Nrf2 
was related to the cellular oxidative stress, we also assessed 
the concentrations of oxPAPC in PBMC. Our results demon-
strate that the concentrations of both PGPC and POVC, the 
oxPAPC considered in this study, were significantly higher 
Table 2 Clinical and laboratory data of non-COPD and COPD 
subjects
Clinical and laboratory 
data
Non-COPD
N?30
COPD
N?30
P-value
Waist circumference (cm) 96.1?11.8 101.3?12.2 NS
BMI (kg/m2) 27.6?4.8 28.3?4.3 NS
SBP (mmHg) 140.6?20.7 130.2?16.9 0.01
DBP (mmHg) 85.1?9.5 80.3?10.6 NS
Total cholesterol (mmol/L) 5.48?0.97 4.87?1.02 0.01
LDL cholesterol (mmol/L) 3.56?0.95 2.89?0.78 0.01
HDL cholesterol (mmol/L) 1.47?0.42 1.34?0.32 NS
Triglycerides (mmol/L) 1.27?0.67 1.48?0.7 NS
Plasma glucose (mmol/L) 5.64?1.45 5.79?1.12 NS
hsCRP (mg/L) 1.07?0.51 2.72?1.32 0.01
White blood count (mm3) 6,160?1,500 7,199?1,940 0.02
Note: Data are expressed as mean ? SD.
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary 
disease; DBP, diastolic blood pressure; HDL, high-density lipoprotein; hsCRP, high-
sensitivity C-reactive protein; LDL, low-density lipoprotein; NS, not signiﬁcant; 
SBP, systolic blood pressure; SD, standard deviation.
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Figure 1 Nrf2 and HO-1 mRNA and protein expression in PBMC of non-COPD and COPD subjects.
Notes: (A) mRNA expression of Nrf2 and HO-1. mRNA was analyzed by quantitative real-time PCR; normalized gene expression levels are given as the ratio between the 
mean value for the target gene and ?-actin in each sample. Data are expressed as mean ? SD; *P?0.001 versus non-COPD. (B) Representative Western blot analysis for 
the indicated proteins and average quantiﬁcation obtained by densitometric analysis of all the samples derived from non-COPD and COPD subjects. Row 1, target protein; 
row 2, ?-actin; row 3, lamin B. Data are expressed as mean ? SD; *P?0.001 versus non-COPD.
Abbreviations: COPD, chronic obstructive pulmonary disease; HO-1, heme oxygenase-1; mRNA, messenger RNA; Nrf2, nuclear factor-E2-related factor 2; PBMC, 
peripheral blood mononuclear cells; PCR, polymerase chain reaction; SD, standard deviation.
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Figure 2 UPR mRNA and protein expression in PBMC of non-COPD and COPD subjects.
Notes: (A) mRNA expression of BiP, ATF6, PERK, IRE1, and CHOP. mRNA was analyzed by quantitative real-time PCR; normalized gene expression levels are given as the 
ratio between the mean value for the target gene and ?-actin in each sample. Data are expressed as mean ? SD. (B) Representative Western blot analysis for the indicated 
proteins (BiP, ATF6, PERK, IRE1, and CHOP) and the average quantiﬁcation obtained by densitometric analysis of all the samples derived from non-COPD and COPD 
subjects. Row 1, target protein; row 2, ?-actin. Data are expressed as mean ? SD.
Abbreviations: ATF6, activating transcription factor 6; BiP, binding immunoglobulin protein; CHOP, CCAAT/enhancer-binding protein homologous protein; COPD, 
chronic obstructive pulmonary disease; IRE1, inositol-requiring kinase 1; mRNA, messenger RNA; PBMC, peripheral blood mononuclear cells; PCR, polymerase chain 
reaction; PERK, protein kinase-like ER kinase; SD, standard deviation; UPR, unfolded protein response.
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Figure 3 MDA and GSH plasma concentrations in non-COPD and COPD 
subjects.
Notes: Data are expressed as mean ? SD; *P?0.01 versus non-COPD.
Abbreviations: COPD, chronic obstructive pulmonary disease; GSH, glutathione; 
MDA, malondialdehyde; SD, standard deviation.
(P?0.01) in PMBC derived from COPD than non-COPD 
subjects (Figure 4). Moreover, we found a significant direct 
correlation between plasma MDA and both PGPC (r?0.47, 
P?0.001) and POVPC (r?0.50, P?0.001) in PBMC of all 
subjects (data not shown). As oxPAPC has been shown to 
act as a second messenger in triggering NADPH oxidase 
activity,26 the expression of p47phox was also evaluated. 
Our results show an increased mRNA and protein expres-
sion (P?0.001) of p47phox in PBMC derived from COPD 
compared to non-COPD subjects (Figure 5A and B). 
Moreover, we found a positive correlation between the 
expression of p47phox and the concentrations of both 
PGPC (r?0.36, P?0.005) and POVPC (r?0.44, P?0.001) in 
PBMC of all subjects (Figure 5C and D), Finally, as shown 
in Figure 6, p47phox mRNA expression directly correlated 
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Figure 4 oxPAPC (PGPC and POVPC) concentrations in PBMC of non-COPD and 
COPD subjects.
Notes: Data represent the mean ? SD of measurements performed in triplicate in 
all subjects; *P?0.01 versus non-COPD.
Abbreviations: COPD, chronic obstructive pulmonary disease; oxPAPC, 
oxidation products of the phospholipid 1-palmitoyl-2-arachidonyl-sn-glycero-3-
phosphorylcholine; PBMC, peripheral blood mononuclear cells; PGPC, 1-palmitoyl-
2-glutaroyl-sn-glycero-3-phosphorylcholine; POVPC, 1-palmitoyl-2-(5-oxovaleroyl)-
sn-glycero-3-phosphorylcholine; SD, standard deviation.
with Nrf2 mRNA expression (r?0.52, P?0.001) in PBMC 
of all subjects.
Relationship between lung function and 
circulating markers of oxidative stress 
and antioxidant gene expression
Figure 7A and B shows that lung function, expressed as 
FEV1 (% predicted), directly correlated with plasma con-
centrations of GSH (r?0.61, P?0.001) and inversely with 
plasma concentrations of MDA (r??0.46; P?0.001) in all 
the subjects participating in the study. Furthermore, our 
results also demonstrate an inverse relationship between 
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Figure 5 p47phox mRNA and protein expression in PBMC of non-COPD and COPD and correlations between p47phox mRNA expression and PGPC and POVPC 
concentrations in PBMC of all subjects.
Notes: (A) mRNA expression of p47phox. mRNA was analyzed by quantitative real-time PCR; normalized gene expression levels are given as the ratio between the 
mean value for the target gene and ?-actin in each sample. Data are expressed as mean ? SD. *P?0.001 versus non-COPD. (B) Representative Western blot analysis for 
p47phox protein and the average quantiﬁcation obtained by densitometric analysis of all the samples derived from non-COPD and COPD subjects. Data are expressed as 
mean ? SD; *P?0.001 versus non-COPD. (C) Correlation between p47phox mRNA expression and PGPC concentrations in PBMC of all non-COPD and COPD subjects. 
(D) Correlation between p47phox mRNA expression and POVPC concentrations in PBMC of all non-COPD and COPD subjects.
Abbreviations: COPD, chronic obstructive pulmonary disease; mRNA, messenger RNA; PAPC, 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine; PBMC, 
peripheral blood mononuclear cells; PGPC, 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphorylcholine; POVPC, 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine; 
SD, standard deviation.
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Figure 6 Correlation between p47phox and Nrf2 mRNA expression in PBMC of all 
non-COPD and COPD subjects.
Abbreviations: COPD, chronic obstructive pulmonary disease; mRNA, 
messenger RNA; Nrf2, nuclear factor-E2-related factor 2; PBMC, peripheral blood 
mononuclear cells.
FEV1 and both Nrf2 (r??0.53, P?0.001) and HO-1 (r??0.50, 
P?0.001) mRNA expression in PBMC (Figure 7C and D) 
of all the subjects.
Discussion
COPD is characterized by a slowly progressive development 
of irreversible airflow limitation in which persistent CS-in-
duced oxidative stress and inflammation are recognized as 
the major pathogenetic factors.4,5 Evidence indicates that CS 
cessation is effective in reducing mortality and delaying, but 
not halting, the rate of lung function decline in patients with 
mild COPD,27 so that it is possible to speculate that oxidative 
stress and inflammation may persist even after CS ending.3,28 
The studies performed in the last decades on this issue have 
included mainly moderate–severe COPD patients with dif-
ferent CS exposure (current and ex-smokers, as well as 
subjects who had never smoked).3,29,30 On the contrary, very 
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scarce data are available in ex-smoker COPD patients with 
a less severe airway obstruction. Therefore, a first important 
feature of this study is the peculiar setting of the subjects, 
that is, mild–moderate ex-smokers with COPD, compared 
with age- and sex-matched non-COPD ex-smoker subjects. 
Although recent studies suggest that PBMC gene expression 
may represent a promising noninvasive useful alternative to 
biopsy or invasive procedures especially at an early stage of 
the disease and a possible expression of systemic involvement 
of COPD,31,32 the majority of data available so far come from 
airway cells or lung tissues.9,14,15 In this study, we have first 
evaluated the expression of Nrf2 and of HO-1 (one of its 
main target genes) because several studies have shown that 
Nrf2 and its Nrf2 downstream genes have an essential protec-
tive role in the lung against oxidative stress.29,30,33–35 Rather 
unexpectedly, we demonstrated an increased expression of 
both Nrf2 and HO-1 in PBMC derived from ex-smokers with 
COPD compared with ex-smokers non-COPD. Although this 
finding confirms that PBMC may be a suitable noninvasive 
tool in mild–moderate COPD, it is not in line with prior 
reports showing a decline of Nrf2 expression in whole lung 
tissue,9,30 alveolar macrophages of current smokers,9 and 
patients with COPD.29,30 In these studies, the decrease of Nrf2 
in alveolar macrophages and lung tissues of patients with 
emphysema was due to an increase of Bach-1 and Kelch-like 
ECH-associated protein 129 or a loss of Nrf2 protein 
stability.30 Similarly, it has been previously shown that the 
expression of HO-1 was diminished in pulmonary mac-
rophages from patients with severe emphysema.29,33 Hence, 
at variance with previous studies performed in patients with 
different smoking exposure9,17 and/or COPD stages,29,30,36 our 
finding shows that in ex-smokers with mild–moderate 
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Figure 7 Correlations between lung function (expressed as FEV1 % predicted) and circulating markers of oxidative stress and antioxidant mRNA expression in all non-COPD 
and COPD subjects.
Notes: (A) Correlation between FEV1 and MDA plasma concentration in all non-COPD and COPD subjects. (B) Correlation between FEV1 and GSH plasma concentration 
in all non-COPD and COPD subjects. (C) Correlation between FEV1 and Nrf2 mRNA expression in PBMC of all non-COPD and COPD subjects. (D) Correlation between 
FEV1 and HO-1 mRNA expression in PBMC of all non-COPD and COPD subjects.
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; GSH, glutathione; HO-1, heme oxygenase-1; MDA, 
malondialdehyde; mRNA, messenger RNA; Nrf2, nuclear factor-E2-related factor 2; PBMC, peripheral blood mononuclear cells; pred, predicted.
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bronchial obstruction, the antioxidant Nrf2/ARE is overex-
pressed in PBMC. Another peculiar result of this study is 
that UPR and CHOP expression in PBMC was similar in 
both groups of subjects. Recent studies have demonstrated 
the involvement of CS in UPR and, in particular, that CS 
caused a UPR response in the airway cells12 and human lungs, 
which is partially reversible after CS cessation.13 However, 
as far as COPD is concerned, the results are not completely 
in agreement; in fact, while some authors reported that UPR 
and apoptosis progressively increase in the lungs of ex- and 
current smokers with normal lungs, with mild and advanced 
COPD,14 an absence of ER stress in the lungs of patients with 
severe COPD has also been reported.37 Recent evidence 
indicates that there is a crosstalk between Nrf2 and UPR; it 
has been shown that impaired Nrf2 expression exaggerated 
ER stress and apoptosis in mice after exposure to CS8 and 
increased apoptosis in alveolar macrophages of smoker 
COPD subjects.38 Moreover, we have recently shown an 
increased ER stress with Nrf2 repression in PBMC derived 
from stable coronary artery disease patients.39 On the con-
trary, the results of a very recent in vitro study indicate that 
Nrf2 overexpression reduced CHOP and protected cells from 
apoptosis.40 From a mechanistic point of view, it has been 
recently demonstrated that a Nrf2-dependent regulation of 
26S proteasome system exists,41 a major disposal pathway 
for degradation of misfolded proteins from ER.42 Taken 
together with the results of these previous studies, we are 
tempted to speculate that the activation of Nrf2 found in 
PBMC of our mild–moderate COPD subjects may have a 
role in preventing ER stress response in PBMC. Although 
recent studies suggest that a short period of CS cessation 
reduces, but not normalizes oxidative stress in airways43 and 
plasma44 of COPD patients, it is uncertain whether systemic 
oxidative stress is still present after long-term CS cessation. 
To our knowledge, this is the first demonstration of an oxi-
dative–antioxidative imbalance, that is, increased plasma 
levels of MDA and decreased plasma levels of GSH after a 
long period (?1 year) of CS cessation in mild–moderate 
COPD compared with ex-smoker non-COPD subjects. 
Moreover, as past CS exposure and other cardiovascular risk 
factors were similar in both groups, we may speculate that 
this persistent redox imbalance found in our ex-smoker 
COPD subjects most likely arises from endogenous sources 
of ROS.4 Because oxidative stress is one of the most potent 
stimuli for Nrf2/ARE pathway activation,7 in order to ascer-
tain whether the increased expression of Nrf2 was related to 
the cellular oxidative stress, we have evaluated the concentra-
tions of oxPAPC in PBMC. Our results demonstrate that the 
concentrations of both PGPC and POVPC were significantly 
higher in PBMC derived from COPD than non-COPD sub-
jects. Previous studies have indicated that ROS generation 
is dependent on NADPH oxidase in pulmonary epithelial 
cells45 and that PGPC and POVPC dose-dependently raise 
the generation of ROS in PBMC through the activation of 
NADPH oxidase.17 Consequently, we have evaluated the 
expression of p47phox that has been shown to significantly 
contribute to the activity of NADPH oxidase46 and found an 
increased expression of this enzyme subunit in PBMC 
derived from COPD subjects. The fact that the expression 
of p47phox directly correlated with both PGPC and POVPC 
in PBMC suggests that oxPAPC may play a role in inducing 
cellular oxidative stress. Moreover, we found a direct cor-
relation between the expression of p47phox and Nrf2 in 
PBMC. Although correlations do not permit to distinguish 
between cause and effect, taken together, these results sup-
port the hypothesis that our mild–moderate COPD subjects 
can still increase Nrf2/ARE expression in response to the 
intracellular oxidative stress. In this context, we have already 
shown that a progressive increase of oxidative stress in 
PBMC was associated with the activation of the Nrf2/ARE 
pathway in mild young smokers, whereas in heavy smokers 
this pathway was repressed.17 Moreover, we have previously 
demonstrated that both PGPC17 and oxPAPC47 at low con-
centrations induced the expression of Nrf2 in PBMC while 
at higher concentrations the expression of Nrf2 was repressed. 
We can therefore hypothesize that the increased Nrf2 expres-
sion found in our ex-smokers CODP is likely due to the 
reduced burden of oxidative stress consequent to CS suspen-
sion. This ability to counteract oxidative stress by increasing 
Nrf2 pathway is a novel finding that could have important 
implications because the extensive studies performed in 
models of COPD and COPD patients clearly indicate that 
Nr2 is a key determinant of COPD susceptibility.29,30,33–35 
In this study, we also show that plasma levels of high-sensitivity 
CRP and white blood cells were higher in COPD than in 
non-COPD subjects. Although an improvement in inflam-
mation might be expected after CS cessation, the increase of 
systemic markers of inflammation found in our ex-smokers 
with COPD is in line with previous studies indicating that 
airway inflammation is similar in ex-smokers and smokers 
with COPD.48,49 We might therefore speculate that in our 
COPD subjects the persistent oxidative stress may have a 
role in these results as an imbalance in the oxidant–antioxi-
dant system has been recognized as one of the first events 
that ultimately leads to inflammatory reactions in the lung.4 
Population-based studies strongly reported that reduced lung 
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function, as assessed by FEV1, independent of CS, is a sig-
nificant risk factor for total mortality and in particular for 
cardiovascular morbidity.1,21 The results of this study show 
that FEV1 directly correlated with plasma concentrations of 
GSH and inversely with MDA in all subjects participating 
in the study suggesting that in ex-smokers also oxidant–
antioxidant imbalance may be associated with lung function. 
These results agree with previous data showing, albeit in 
different COPD subjects, that an oxidative stress marker 
inversely correlated with lung function.5 Our finding of an 
inverse correlation between FEV1 and both Nrf2 and HO-1 
expression in PBMC supports the hypothesis that ex-smokers 
with mild–moderate COPD can properly respond in terms 
of Nrf2 and HO-1 expression to lung function decline. Our 
data are in line with a former study showing that HO-1 
expression in lung homogenates of severe COPD patients was 
inversely correlated with airway obstruction and increased 
macrophage expression of oxidative stress markers.29 At 
variance with these results, a direct correlation between lung 
function (FEV1:FVC) and mRNA expression of Nrf2 target 
antioxidant genes in lung of COPD subjects has been previ-
ously shown.30 Based on recent evidence suggesting that the 
pharmacological activation of Nrf2 protects mice against 
CS-induced emphysema,50 it has been proposed that the new 
Nrf2 inducers, also called “indirect antioxidants”,51 may be 
a useful tool for preventing and treating COPD. Thus, as 
there are currently no treatments that significantly reverse or 
slow the progression of COPD,4 the future possibility to 
counteract Nrf2 decline in COPD patients may help in reduc-
ing the negative effects of the oxidative stress-induced 
progression of the disease.
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